Literature DB >> 29587841

Physical activity in the morning and afternoon is lower in patients with chronic obstructive pulmonary disease with morning symptoms.

Amanda R van Buul1, Marise J Kasteleyn2,3, Niels H Chavannes3, Christian Taube2,4.   

Abstract

BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) experience symptoms that vary over the day. Symptoms at the start of the day might influence physical activity during the rest of the day. Therefore, physical activity during the course of the day was studied in patients with low and high morning symptom scores.
METHODS: This cross-sectional observational study included patients with moderate to very severe COPD. Morning symptoms were evaluated with the PRO-morning COPD Symptoms Questionnaire (range 0-60); the median score was used to create two groups (low and high morning symptom scores). Physical activity was examined with an accelerometer. Activity parameters during the night, morning, afternoon and evening were compared between patients with low and high morning symptom scores using independent t-tests or Mann-Whitney U tests.
RESULTS: Seventy nine patients were included. Patients were aged (mean ± SD) 65.6 ± 8.8 years with a mean forced expiratory volume in 1 s of 55 ± 17%predicted. Patients with low morning symptom scores (score < 17.0) took more steps in the afternoon (p = 0.015) and morning (p = 0.030). There were no significant differences during the evening and night.
CONCLUSION: Patients with high morning symptom scores took significantly fewer steps in the morning and afternoon than those with low morning symptom scores. Prospective studies are needed to prove causality between morning symptoms and physical activity during different parts of the day.

Entities:  

Keywords:  Afternoon; Chronic obstructive pulmonary disease; Evening; Morning; Morning symptoms; Physical activity

Mesh:

Year:  2018        PMID: 29587841      PMCID: PMC5870529          DOI: 10.1186/s12931-018-0749-4

Source DB:  PubMed          Journal:  Respir Res        ISSN: 1465-9921


Background

Chronic obstructive pulmonary disease (COPD) is a worldwide problem with a high prevalence of years lived with disability [1]. COPD is associated with dyspnoea, fatigue and decreased physical activity. Regular physical activity in patients with COPD is associated with a lower risk of admissions and mortality [2]. Most previous studies reported on physical activity during day time solely [3-6]. When physical activity was measured over the course of the day, nuanced reporting on physical activity during different parts of the day was generally lacking [7-10]. Therefore, only little is known about physical activity in COPD patients during the night and early morning. Studying physical activity during the course of the day is important, because a symptomatic start to the day might influence physical activity during the rest of the day. Patients with COPD experience the morning as most symptomatic part of the day [11, 12] and the night as second most symptomatic part of the day [12]. Studies have shown that morning symptoms are negatively associated with self-reported physical activity [13]. A negative association between morning symptoms and overall physical activity has been reported [14]. However, the relation between morning symptoms and objectively measured physical activity during different parts of the day has not been studied yet. From previous research it is known that morning symptoms influence self-care, housework and work activities [15]. We hypothesized that patients with high morning symptom scores are less active in the morning and during the rest of the day compared to patients with low morning symptom scores. Furthermore, detailed assessments of physical activity over the day could give insight which part might be most suitable for physical activity interventions. Therefore, the primary aim of this study was to examine physical activity during the course of the day depending on morning symptoms. In addition, self-reported physical activity was assessed to better understand which types of activities were generally undertaken.

Methods

Research design

The Morning symptoms in-Depth observAtional Study (MODAS) was a single centre, observational, cross-sectional study (study NL51951.058.15; www.toetsingonline.nl). The study was conducted from September 2015 to February 2017. The medical ethics committee from the Leiden University Medical Center (LUMC) approved the study protocol.

Participants

Detailed inclusion/exclusion criteria have been reported previously [14]. In summary, included in the study were patients aged 40 to 80 years. A physician had diagnosed them with COPD. They had moderate to very severe airflow limitation according to the Global initiative for Obstructive Lung Disease (GOLD) definitions [16]. Patients were exacerbation-free for at least 2 months. They were current or active smokers with at least 10 pack-years. Main exclusion criteria were the diagnosis of asthma; significant other lung disease, comorbidities and severe pain syndromes that impair exercise capacity. Patients were recruited from the LUMC and Alrijne hospital in Leiden (The Netherlands). Patients who were considered to be eligible were notified about the study by telephone or during an outpatient visit. Furthermore, patients were recruited by flyers in local papers. Eligible interested patients received an information letter. If the patient agreed to participate in the study, a study visit was scheduled. During the visit, written informed consent was obtained.

Assessments

During the baseline visit, demographic data and comorbidities were obtained by a physician. Patients were asked about their medication use and this was verified with a medication overview of the pharmacy. COPD-specific health-related quality-of-life, morning symptoms severity, self-reported physical activity and pre- and post-bronchodilator pulmonary function were assessed at the study center. After this visit, patients wore a triaxial accelerometer for seven consecutive days to objectively assess physical activity. When the physical activity measurements were finished, there was a follow-up telephone interview to report possible adverse events. Morning symptom severity was evaluated with the PRO-Morning COPD Symptoms Questionnaire (pre-morning doses assessment) [17]. This questionnaire consists of six questions about dyspnoea, cough, sputum production, wheezing, chest tightness and limitations in the morning. Patients rated the severity of these symptoms with a Likert scale from 0 to 10 points. 0 for no symptoms; 10 points for symptoms as bad as they can imagine. The total score ranged from 0 to 60. Physical activity was objectively measured with an accelerometer (Dynaport MoveMonitor, McRoberts BV, The Hague, the Netherlands) [18, 19]. This accelerometer was worn on the waist during the entire day for seven consecutive days resulting in real-life activity recording. To give insight into physical activity over the course of the day, days were divided in four parts of the day of each 6 hours: night (00.00 to 06.00), morning (06.00 to 12.00), afternoon (12.00 to 18.00) and evening (18.00 to 00.00). Duration of activity (standing, shuffling and walking) and inactivity (sitting and lying) in minutes was registered. The number of steps was recorded per part of the day and per hour. Patients were not allowed to wear the accelerometer during bathing or showering. The duration that the accelerometer was not worn was automatically registered. A measurement was considered valid when patients wore the accelerometer at least 90% per part of the day. Averages of the outcomes of valid parts of the day were calculated for each patient. Patients with only invalid parts of the day were excluded from analysis. Patients filled out the Dutch version of the international physically activity questionnaire (IPAQ) [20]. In this questionnaire patients reported the number of minutes per day and days per week they were physical active in a 7-day period. Physical activity was categorized in four domains: work, transport, housework or leisure time related. Patients who reported more than 960 min a day each day of the week were excluded from this analysis in line with the activity calculation instructions of the IPAQ. The Charlson Co-morbidity index was used to evaluate comorbidities (CCI) [21] and the three most common comorbidities were reported as percentage. COPD-specific health-related quality-of-life was assessed with the St George’s Respiratory Questionnaire (SGRQ), [22] health status with the Clinical COPD Questionnaire (CCQ) [23] and dyspnoea in daily living with the medical modified research council (mMRC) [24]. All patients performed pre- and post-bronchodilator spirometry following ERS/ATS (European Respiratory Society/American Thoracic Society) standards in the morning between 08.30 and 11.00 (Care Fusion, Masterscreen PFT). [25-27] In this study, reported spirometry outcomes were post-bronchodilator values. Forced volume in 1 second (FEV1) was expressed in % predicted values (based on the Global Lung Function Initiative 2012) [26].

Statistical analysis

Descriptive data were reported as percentages, mean values ± standard deviations (SD) for normal distributed continuous variables and median with interquartile ranges (IQR) for non-normal distributed continuous variables. The study cohort was divided in two equal groups using the median score on the PRO-morning COPD Symptoms Questionnaire as cut-off. Differences in baseline characteristics between the two groups were compared with an independent t-test for continuous normal distributed variables; a Mann-Whitney U test for continuous non-normal distributed variables and chi-square test for categorical variables. Differences in steps during the total day were compared between patients with low and high morning symptom scores using an independent t-test. Difference in steps and duration of (in)activity during different parts of the day were compared using an independent t-test or Mann-Whitney U test. To give an overview of the number of steps over the course of the day, steps per hour were plotted against hour of the day. Self-reported physical activity was compared using a Mann-Whitney U test. An explorative subgroup analysis was performed to examine long-acting pulmonary medication use. Long-acting pulmonary medication use was categorized in three groups: double bronchodilation (combination of a long-acting beta2 agonist (LABA) and long-acting muscarinic antagonist (LAMA)), a single bronchodilator (LABA or LAMA use) or no use of long-acting pulmonary medication. The difference in mean number of steps in the morning was evaluated with a one way ANOVA. Steps per hour were plotted against hour of the day for patients with low and high dyspnoea scores in daily living [16] to evaluate the impact of using a general symptom questionnaire instead of a specific morning symptom questionnaire to divide the study group. A sensitivity analysis was performed to evaluate the impact of adverse events during the study period; all patients who reported an adverse events, defined as self-reported illness or any somatic symptom for which the patient had to visit a health care provider, were excluded from the analyses. For all analyses, a p-value of < 0.05 was considered statistically significant. Missing data was not replaced. We used SPSS version 23 to perform the analyses.

Results

Patients

From 168 eligible patients who received the patient information form, 80 patients were included in the study and 79 patients had sufficient outcomes from accelerometry for analyses (Fig. 1). Table 1 shows demographics and baseline characteristics. Patients were (mean ± SD) 65.6 ± 8.8 years old and 53% were male. They had a mean FEV1 of 55 ± 17% predicted. Most patients were classified as COPD GOLD D (40.5%) and B (27.8%). Mean morning symptom score was 17.9 ± 11.8 with a range between 0 and 47. The median morning symptom score was 17.0 and was used as cut-off to separate the study cohort in two equal groups (Table 1).
Fig. 1

Study flow diagram

Table 1

Baseline characteristics

CharacteristicAll included patients (N = 79)Morning symptom score < 17.0 (N = 41)Morning symptom score ≥ 17.0 (N = 38)Difference (P-value)
Age in years, mean (SD)65.6 (8.8)66.4 (8.2)64.7 (9.4)0.38
Male, n (%)42 (53)25 (61)17 (45)0.15
Ethnicity Caucasian, n (%)78 (99)40 (98)38 (100)0.33
Current smoking, n (%)21 (27)8 (20)13 (34)0.14
Pack years, median [IQR]37 [25–51]34 [25–42]41 [26–71]0.06
In current employment, n (%)21 (27)12 (29)9 (24)0.58
BMI in kg/m2, mean (SD)26.4 (5.1)25.5 (4.8)27.3 (5.3)0.13
FEV1/FVC ratio, mean (SD)45.5 (12.2)45.6 (13.6)45.5 (10.6)0.99
FEV1% predicted, mean (SD)55.2 (16.9)57.2 (19.3)53.0 (14.0)0.28
Exacerbation in the previous year, n (%)41 (52)16 (39)25 (66)0.017
GOLD stage
 A, n (%)19 (24.1)17 (41.5)2 (5.3)< 0.001
 B, n (%)22 (27.8)9 (22.0)13 (34.2)0.23
 C, n (%)6 (7.6)6 (14.6)0 (0.0)0.014
 D, n (%)32 (40.5)9 (22.0)23 (60.5)< 0.001
CCQ total score, mean (SD)2.1 (1.1)1.4 (0.86)2.8 (0.9)< 0.001
SGRQ total score, mean (SD)43.0 (18.6)32.1 (16.6)54.8 (12.4)< 0.001
Long-acting bronchodilation
 Use of one long-acting bronchodilator, n (%)17 (21.5)10 (24.4)7 (18.4)0.52
 Use of two long-acting bronchodilators, n (%))58 (74.7)28 (68.3)31 (81.6)0.18
 No long-acting bronchodilator, n (%)3 (3.8)3 (7.3)0 (0.0)0.09
CCI score, median [IQR]2 [1–3]2 [1–3]2 [1–3]0.98
 History of solid tumor without metastasis, n (%)15 (19.0)9 (22.0)6 (15.8)0.49
 Cerebrovascular disease, n (%)10 (12.7)6 (14.6)4 (10.5)0.58
 Uncomplicated diabetes mellitus, n (%)9 (11.4)3 (7.3)6 (15.8)0.24

BMI body mass index, CCI Charlson comorbidity index, CCQ clinical COPD questionnaire, FEV Forced expiratory volume in 1 s, FVC forced vital capacity, GOLD global initiative for chronic obstructive lung disease, IQR interquartile range, SD standard deviation, SGRQ St George Respiratory Questionnaire

Study flow diagram Baseline characteristics BMI body mass index, CCI Charlson comorbidity index, CCQ clinical COPD questionnaire, FEV Forced expiratory volume in 1 s, FVC forced vital capacity, GOLD global initiative for chronic obstructive lung disease, IQR interquartile range, SD standard deviation, SGRQ St George Respiratory Questionnaire

Physical activity

Seventy nine patients wore the accelerometer 7 consecutive days. Thus, data from 553 days were collected from these 79 patients. 95.8% of the night, 91.0% of the morning, 96.7% of the afternoon and 93.9% the evening measurements fulfilled the quality standards and were included in the analysis. In each part of the day, most of the time was spent in inactivity (Table 2).
Table 2

Duration of different types of activity during the morning, afternoon, evening and night (N = 79)

ActivityTotal duration in mean min (SD)
MorningAfternoonEveningNight
Active timea85.5 (39.7)112.4 (42.3)57.2 (34.1)8.8 (10.1)
 Standing54.9 (25.4)67.8 (25.5)38.7 (25.9)6.1 (7.4)
 Shuffling8.7 (5.4)11.6 (6.7)5.2 (4.1)0.8 (1.0)
 Walking22.0 (15.1)33.0 (20.0)13.2 (9.8)1.9 (2.4)
Inactive timeb271.6 (39.7)246.7 (42.0)302.0 (34.1)351.1 (10.1)
 Lying150.6 (63.9)42.9 (45.8)105.7 (78.5)327.3 (51.2)
 Sitting120.9 (44.7)203.8 (45.6)196.3 (72.4)23.8 (43.3)
Not worn2.9 (4.7)1.0 (1.8)0.9 (2.2)0.2 (0.7)

aActive: standing, shuffling and walking combined

binactive: lying and sitting combined. SD: standard deviation

Duration of different types of activity during the morning, afternoon, evening and night (N = 79) aActive: standing, shuffling and walking combined binactive: lying and sitting combined. SD: standard deviation Mean number of steps per day was (mean ± SD) 5686 ± 3514. Patients with low morning symptom scores took 6598 ± 4243 steps a day; those with high morning symptom scores 4727 ± 2209 steps a day (mean difference 1871, p = 0.017). Patients with high morning symptom scores took significantly fewer steps during the morning (mean difference 669, p = 0.030) and during the afternoon (mean difference 1013, p = 0.015) than patients with low morning symptom scores (Table 3). Patients with low morning symptom scores were active for longer during the afternoon (mean difference 19, p = 0.040) and spent more minutes walking during the morning (mean difference 8, p = 0.020) and afternoon (mean difference 11, p = 0.010). There were peaks in mean number of steps at 15:00 (550 steps per hour) and at 12:00 (535 steps per hour) (Fig. 2). When patients with low and high morning symptom scores were categorized on medication use, there was no significant difference in mean number of steps in the morning between the groups (p = 0.057) (Additional file 1: Figure S1). When patients were categorized on high and low mMRC score, there was a significant difference in number of steps in the morning, afternoon and evening (Additional file 2: Figure S2).
Table 3

Differences in duration of activity during the night, morning, afternoon and evening between COPD patients with low and high morning symptom scores

Morning symptom score < 17.0 (N = 41)Morning symptoms score ≥ 17.0 (N = 38)P-value
StepsNight97 [50–173]92 [50–138]0.60
Morning2117 (1552)1448 (1069)0.030
Afternoon3196 (2352)2183 (1025)0.015
Evening1145 (858)943 (861)0.30
Active time (in min, mean (SD) or median [IQR])Night6 [2–11]6 [3–10]0.76
Morning91 (39)79 (40)0.18
Afternoon122 (45)102 (38)0.040
Evening52 [37–79]42 [33–77]0.19
Standing (in min, mean (SD) or median [IQR])Night3 [1;7]4 [2;8]0.62
Morning56 (24)53 (28)0.61
Afternoon71 (25)64 (26)0.23
Evening40 (24)37 (28)0.59
Shuffling (in min, mean (SD) or median [IQR])Night0 [0;1]1 [0;1]0.77
Morning9 (6)8 (5)0.33
Afternoon12 (7)11 (6)0.44
Evening5 [2;8]4 [2;6]0.32
Walking (in min, mean (SD) or median [IQR])Night13 [7–19]9 [6–15]0.11
Morning26 (17)18 (12)0.020
Afternoon38 (24)27 (12)0.010
Evening15 (10)12 (10)0.23
Inactive time (in min, mean (SD) or median [IQR])Night354 [349–358]354 [350–357]0.88
Morning265 (40)278 (39)0.14
Afternoon238 (44)257 (37)0.043
Evening299 (33)305 (36)0.41
Lying (in min, mean (SD) or median [IQR])Night343 [322–353]343 [330–355]0.89
Morning140 (52)161 (74)0.15
Afternoon27 [5–50]34 [12–68]0.14
Evening90 [44–138]83 [53–151]0.71
Sitting (in min, mean (SD) or median [IQR])Night9 [3–22]10 [2–22]0.74
Morning125 (38)117 (51)0.45
Afternoon203 (41)205 (51)0.85
Evening198 (68)195 (78)0.86

Night N = 78, morning N = 78, afternoon N = 79, evening N = 78

COPD chronic obstructive pulmonary disease, IQR interquartile range, SD standard deviation

Fig. 2

Steps during each hour of the day, Low morning symptom score: score < 17.0; high morning symptom score: score ≥ 17.0

Differences in duration of activity during the night, morning, afternoon and evening between COPD patients with low and high morning symptom scores Night N = 78, morning N = 78, afternoon N = 79, evening N = 78 COPD chronic obstructive pulmonary disease, IQR interquartile range, SD standard deviation Steps during each hour of the day, Low morning symptom score: score < 17.0; high morning symptom score: score ≥ 17.0

Self-reported daily activities

Patients’ median [IQR] self-reported physical activity was 715 [319;1448] minutes a week. Patients spent most of their self-reported physical activity during leisure time (Table 4). Patients with low morning symptom scores spent significantly more time in transport and leisure time activities than those with high morning symptom scores. No significant differences were found for work, housework activities and total activity.
Table 4

Self-reported daily activities

IPAQTotal (N = 70)aMorning symptom score < 17.0 (N = 34)Morning symptom score ≥ 17.0 (N = 36)Difference (p-value)
Work, in min/week, median [IQR]0 [0;0]0 [0;30]0 [0;0]0.13
Transport, in min/week, median [IQR]155 [11–319]195 [53–514]68 [0–270]0.047
Housework, house maintenance and caring for family, in min/week, median [IQR]120 [0–608]105 [0–495]150 [0–698]0.89
Recreation, sport and leisure time in min/week, median [IQR]160 [0–420]293 [15–604]60 [0–263]0.017
Total activity min/week, median [IQR]715 [219–1448]935 [533–1808]665 [131–1298]0.13

a9 out of 79 patients were excluded: 6 patients did not fully complete the IPAQ; 3 patients filled out unreasonably high time in physical activity (more than 960 min a day each day of the week)

IPAQ international physical activity questionnaire, IQR interquartile range

Self-reported daily activities a9 out of 79 patients were excluded: 6 patients did not fully complete the IPAQ; 3 patients filled out unreasonably high time in physical activity (more than 960 min a day each day of the week) IPAQ international physical activity questionnaire, IQR interquartile range

Sensitivity analysis

Seven patients reported an adverse event. One patient was exhausted due to the study visit, two patients reported pain in their hands, one had pneumonia, one had flu, one had sinusitis and one patient reported a visit to her general practitioner who prescribed a course of antibiotics and prednisone for pulmonary complaints. There were no serious adverse events. Patients with adverse events have a significant lower quality of life and reported higher morning symptom scores (Additional file 3: Table S1). When excluding the patients with an adverse event from analyses, the cut-off n the PRO-morning COPD Symptoms Questionnaire to divide the cohort in two equal groups decreased to 15.0, since all patients with an adverse event were categorized in the high morning symptom score group. Results were nearly similar (Additional file 3: Table S2 and S3 and Additional file 4: Figure S3) apart from that there was no difference anymore in number of steps in the morning between patients with low and high morning symptom scores.

Discussion

This study was designed to evaluate physical activity during the course of the day in patients with moderate to severe COPD with low and high morning symptom scores. This is one of the first studies that explored physical activity in more detail during the course of the day using objective methodology. We showed that patients with high morning symptom scores took significantly fewer steps in the morning and afternoon than those with low morning symptom scores. There were no differences in physical activity in the evening and night between these two groups. Patients with high morning symptom scores spent less time in transport and leisure time than patients with low morning symptom scores. The present study showed that patients with high morning symptom scores took fewer steps during the total day. This is in line with previous studies that have shown that daily symptoms were associated with lower physical activity levels [10]. One study in a primary care setting in men who are aged between 71 and 92 years, of whom 50% had chronic conditions, [28] reported that men were most active in the morning, followed by a substantial decline in steps per hour, with peaks at times 10:00, 14:00 and 22:00. Our study showed that the afternoon is the most active part of the day for patients with COPD with peaks in steps per hour at times 12:00 and 15:00. Thus, patients with COPD have different activity patterns during the course of the day. These findings are in line with another study of activity in COPD patients; this study showed the highest activity levels during the late morning and early afternoon, followed by a decline in activity [5]. The difference in activity patterns between older men and COPD patients could possibly be explained by known activity characteristics that are typical for COPD patients: lower walking speed, [29] walking with increased duration in time between steps, [30] doing activities slower, [12] taking more breaks, [12] performing daily activities in fewer bouts [4] and shorter bouts [4]. When analysing the activity patterns in a more detailed way, the present study showed that patients with high morning symptom scores were less active during the morning and afternoon than patients with low morning symptom scores. Systematic reviews have shown that multiple determinants have impact on physical activity [31] and that morning symptoms are associated with physical activity [13]. The etiology of morning symptoms is unknown. It can be speculated that inactivity in the afternoon in patients with high morning symptom scores could be due to the long-lasting effects of morning symptoms. It could also be true that patients with morning symptoms have more symptoms during the rest of the day [32]. Interestingly, we found no difference in active time during the evening and night between patients with low and high morning symptom scores. We did not expect this, because we expected that morning symptoms would be associated with less physical activity during each part of the day as patients reported in previous studies in which physical activity was not objectively measured [15, 33]. Exploring the assumption that morning symptoms influence physical activity in the morning, but not in the evening, the evening might be a suitable part of the day in which physical activity could be enhanced, especially in those with high morning symptom scores. In line with previous research, the present study showed that patients spent most of their self-reported physical activity in leisure time [4]. Patients with high morning symptom scores spent less time in transport and leisure time activities than patients with low morning symptom scores. Encouraging physical activity in leisure time might result in more physical activity and can also increase quality of life [34]. A few previous studies have shown that inhaled medication decreased physical activity limitations due to morning symptoms [15, 35, 36]. An explorative analysis in the present study showed no differences in physical activity between no, single or double long-acting bronchodilator use. However, this study was not powered to show differences in medication use and future research regarding this topic is warranted. A strength of the current study was 24-h a day accelerometry. This resulted in real-life activity recording without missing physical activity during the evening and the night. However, we did not have information regarding the time patients go to bed and woke up. Consequently, patients who got out of bed early in the morning (and were already awake for a couple of hours), were compared with patients who had only just awoken. Previous studies that assessed the association between morning symptoms and physical activity used self-reported questionnaires, while accelerometers are superior in physical activity assessment than questionnaires [13, 37]. Another strength was the inclusion of patients from an academic medical center, a local hospital and patients recruited by flyers in local papers. This resulted in a heterogeneous population that is generalizable to all patients with moderate to very severe COPD. A limitation of the study was that the accelerometer was not waterproof and patients were not allowed to wear it while taking a shower. For some patients, taking a shower is one of the main physical activities during a day, and this activity was not measured. This means, active time was underestimated. A second limitation is that morning symptoms were evaluated with a non-validated questionnaire. However, there is no validated morning symptom questionnaire available yet. Patients filled in the questionnaire at the study center and not at home at the time they woke up. This might have result in recall bias that might cause higher (or lower) total morning symptom scores. The mean morning symptom score was slightly higher than in a previous study that used the PRO-Morning COPD Symptoms Questionnaire too [17]. Therefore, it could be possible that the cut-off point to separate high from low morning symptom scores was too high. However, when patients with an AE were removed and the cut-off point dropped to 15.0, the outcomes were nearly the same. Another limitation is the observational design of the study. Therefore, it is not possible to prove whether morning symptoms are fully responsible for the differences in physical activity or that physical inactivity itself resulted in more symptoms due to muscle depletion and loss of physical condition. The ERS reported in the physical activity statement in COPD that there are only a few randomised controlled trials that studied effects of treatment on physical activity and that there is a need for additional well-designed trials [29]. Taking the outcomes of this study into account, we suggest for future research to focus on two targets to improve physical activity: first, study the etiology of morning symptoms It would be valuable to measure night time symptoms, the effect of flow-limitation during the night (and the early morning) and the effects of spreading physical activity in relation to morning symptoms. Improvement in morning symptoms consequently might increase the number of steps in the morning and afternoon. Second, develop activity programs that encourage physical activity in the evening in addition to daily physical activities. Physical activity programs can be supported by telecoaching and step counters that provide direct feedback [3].

Conclusion

This study showed that patients with moderate to very severe COPD were most active in the afternoon. Patients with high morning symptom scores took significantly fewer steps in the morning and afternoon than those with low morning symptom scores. Prospective studies are needed to prove causality between morning symptoms and physical activity during different parts of the day. Figure S1. Number of steps in the morning, Error bars present 95% confidence intervals. Low morning symptom score: score < 17.0; high morning symptom score: score ≥ 17.0. (JPEG 192 kb) Figure S2. Steps during each hour of the day, Low mMRC < 2 (N = 27); high mMRC ≥2 (N = 52). (JPEG 195 kb) Table S1. Baseline characteristics for patients with and without an adverse event, Table S2 Differences in activity during the night, morning, afternoon and evening between patient with low and high morning symptom scores, N = 72, Table S3 Daily physical activity. (DOCX 41 kb) Figure S3. Steps during the course of the day, Few morning symptoms: morning symptom score < 15; severe morning symptoms: morning symptom score ≥ 15. (JPEG 203 kb)
  36 in total

1.  Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study.

Authors:  J Garcia-Aymerich; P Lange; M Benet; P Schnohr; J M Antó
Journal:  Thorax       Date:  2006-05-31       Impact factor: 9.139

2.  Patients with Chronic Obstructive Pulmonary Disease Walk with Altered Step Time and Step Width Variability as Compared with Healthy Control Subjects.

Authors:  Jennifer M Yentes; Stephen I Rennard; Kendra K Schmid; Daniel Blanke; Nicholas Stergiou
Journal:  Ann Am Thorac Soc       Date:  2017-06

3.  An official European Respiratory Society statement on physical activity in COPD.

Authors:  Henrik Watz; Fabio Pitta; Carolyn L Rochester; Judith Garcia-Aymerich; Richard ZuWallack; Thierry Troosters; Anouk W Vaes; Milo A Puhan; Melissa Jehn; Michael I Polkey; Ioannis Vogiatzis; Enrico M Clini; Michael Toth; Elena Gimeno-Santos; Benjamin Waschki; Cristobal Esteban; Maurice Hayot; Richard Casaburi; Janos Porszasz; Edward McAuley; Sally J Singh; Daniel Langer; Emiel F M Wouters; Helgo Magnussen; Martijn A Spruit
Journal:  Eur Respir J       Date:  2014-10-30       Impact factor: 16.671

4.  Physical activity in COPD patients: patterns and bouts.

Authors:  David Donaire-Gonzalez; Elena Gimeno-Santos; Eva Balcells; Diego A Rodríguez; Eva Farrero; Jordi de Batlle; Marta Benet; Antoni Ferrer; Joan A Barberà; Joaquim Gea; Robert Rodriguez-Roisin; Josep M Antó; Judith Garcia-Aymerich
Journal:  Eur Respir J       Date:  2012-12-20       Impact factor: 16.671

5.  Methodology for using long-term accelerometry monitoring to describe daily activity patterns in COPD.

Authors:  Ariel Hecht; Shuyi Ma; Janos Porszasz; Richard Casaburi
Journal:  COPD       Date:  2009-04       Impact factor: 2.409

6.  Physical activity in patients with COPD.

Authors:  H Watz; B Waschki; T Meyer; H Magnussen
Journal:  Eur Respir J       Date:  2008-11-14       Impact factor: 16.671

7.  Diurnal patterns of objectively measured physical activity and sedentary behaviour in older men.

Authors:  Claudio Sartini; S Goya Wannamethee; Steve Iliffe; Richard W Morris; Sarah Ash; Lucy Lennon; Peter H Whincup; Barbara J Jefferis
Journal:  BMC Public Health       Date:  2015-07-04       Impact factor: 3.295

8.  Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.

Authors:  Theo Vos; Abraham D Flaxman; Mohsen Naghavi; Rafael Lozano; Catherine Michaud; Majid Ezzati; Kenji Shibuya; Joshua A Salomon; Safa Abdalla; Victor Aboyans; Jerry Abraham; Ilana Ackerman; Rakesh Aggarwal; Stephanie Y Ahn; Mohammed K Ali; Miriam Alvarado; H Ross Anderson; Laurie M Anderson; Kathryn G Andrews; Charles Atkinson; Larry M Baddour; Adil N Bahalim; Suzanne Barker-Collo; Lope H Barrero; David H Bartels; Maria-Gloria Basáñez; Amanda Baxter; Michelle L Bell; Emelia J Benjamin; Derrick Bennett; Eduardo Bernabé; Kavi Bhalla; Bishal Bhandari; Boris Bikbov; Aref Bin Abdulhak; Gretchen Birbeck; James A Black; Hannah Blencowe; Jed D Blore; Fiona Blyth; Ian Bolliger; Audrey Bonaventure; Soufiane Boufous; Rupert Bourne; Michel Boussinesq; Tasanee Braithwaite; Carol Brayne; Lisa Bridgett; Simon Brooker; Peter Brooks; Traolach S Brugha; Claire Bryan-Hancock; Chiara Bucello; Rachelle Buchbinder; Geoffrey Buckle; Christine M Budke; Michael Burch; Peter Burney; Roy Burstein; Bianca Calabria; Benjamin Campbell; Charles E Canter; Hélène Carabin; Jonathan Carapetis; Loreto Carmona; Claudia Cella; Fiona Charlson; Honglei Chen; Andrew Tai-Ann Cheng; David Chou; Sumeet S Chugh; Luc E Coffeng; Steven D Colan; Samantha Colquhoun; K Ellicott Colson; John Condon; Myles D Connor; Leslie T Cooper; Matthew Corriere; Monica Cortinovis; Karen Courville de Vaccaro; William Couser; Benjamin C Cowie; Michael H Criqui; Marita Cross; Kaustubh C Dabhadkar; Manu Dahiya; Nabila Dahodwala; James Damsere-Derry; Goodarz Danaei; Adrian Davis; Diego De Leo; Louisa Degenhardt; Robert Dellavalle; Allyne Delossantos; Julie Denenberg; Sarah Derrett; Don C Des Jarlais; Samath D Dharmaratne; Mukesh Dherani; Cesar Diaz-Torne; Helen Dolk; E Ray Dorsey; Tim Driscoll; Herbert Duber; Beth Ebel; Karen Edmond; Alexis Elbaz; Suad Eltahir Ali; Holly Erskine; Patricia J Erwin; Patricia Espindola; Stalin E Ewoigbokhan; Farshad Farzadfar; Valery Feigin; David T Felson; Alize Ferrari; Cleusa P Ferri; Eric M Fèvre; Mariel M Finucane; Seth Flaxman; Louise Flood; Kyle Foreman; Mohammad H Forouzanfar; Francis Gerry R Fowkes; Richard Franklin; Marlene Fransen; Michael K Freeman; Belinda J Gabbe; Sherine E Gabriel; Emmanuela Gakidou; Hammad A Ganatra; Bianca Garcia; Flavio Gaspari; Richard F Gillum; Gerhard Gmel; Richard Gosselin; Rebecca Grainger; Justina Groeger; Francis Guillemin; David Gunnell; Ramyani Gupta; Juanita Haagsma; Holly Hagan; Yara A Halasa; Wayne Hall; Diana Haring; Josep Maria Haro; James E Harrison; Rasmus Havmoeller; Roderick J Hay; Hideki Higashi; Catherine Hill; Bruno Hoen; Howard Hoffman; Peter J Hotez; Damian Hoy; John J Huang; Sydney E Ibeanusi; Kathryn H Jacobsen; Spencer L James; Deborah Jarvis; Rashmi Jasrasaria; Sudha Jayaraman; Nicole Johns; Jost B Jonas; Ganesan Karthikeyan; Nicholas Kassebaum; Norito Kawakami; Andre Keren; Jon-Paul Khoo; Charles H King; Lisa Marie Knowlton; Olive Kobusingye; Adofo Koranteng; Rita Krishnamurthi; Ratilal Lalloo; Laura L Laslett; Tim Lathlean; Janet L Leasher; Yong Yi Lee; James Leigh; Stephen S Lim; Elizabeth Limb; John Kent Lin; Michael Lipnick; Steven E Lipshultz; Wei Liu; Maria Loane; Summer Lockett Ohno; Ronan Lyons; Jixiang Ma; Jacqueline Mabweijano; Michael F MacIntyre; Reza Malekzadeh; Leslie Mallinger; Sivabalan Manivannan; Wagner Marcenes; Lyn March; David J Margolis; Guy B Marks; Robin Marks; Akira Matsumori; Richard Matzopoulos; Bongani M Mayosi; John H McAnulty; Mary M McDermott; Neil McGill; John McGrath; Maria Elena Medina-Mora; Michele Meltzer; George A Mensah; Tony R Merriman; Ana-Claire Meyer; Valeria Miglioli; Matthew Miller; Ted R Miller; Philip B Mitchell; Ana Olga Mocumbi; Terrie E Moffitt; Ali A Mokdad; Lorenzo Monasta; Marcella Montico; Maziar Moradi-Lakeh; Andrew Moran; Lidia Morawska; Rintaro Mori; Michele E Murdoch; Michael K Mwaniki; Kovin Naidoo; M Nathan Nair; Luigi Naldi; K M Venkat Narayan; Paul K Nelson; Robert G Nelson; Michael C Nevitt; Charles R Newton; Sandra Nolte; Paul Norman; Rosana Norman; Martin O'Donnell; Simon O'Hanlon; Casey Olives; Saad B Omer; Katrina Ortblad; Richard Osborne; Doruk Ozgediz; Andrew Page; Bishnu Pahari; Jeyaraj Durai Pandian; Andrea Panozo Rivero; Scott B Patten; Neil Pearce; Rogelio Perez Padilla; Fernando Perez-Ruiz; Norberto Perico; Konrad Pesudovs; David Phillips; Michael R Phillips; Kelsey Pierce; Sébastien Pion; Guilherme V Polanczyk; Suzanne Polinder; C Arden Pope; Svetlana Popova; Esteban Porrini; Farshad Pourmalek; Martin Prince; Rachel L Pullan; Kapa D Ramaiah; Dharani Ranganathan; Homie Razavi; Mathilda Regan; Jürgen T Rehm; David B Rein; Guiseppe Remuzzi; Kathryn Richardson; Frederick P Rivara; Thomas Roberts; Carolyn Robinson; Felipe Rodriguez De Leòn; Luca Ronfani; Robin Room; Lisa C Rosenfeld; Lesley Rushton; Ralph L Sacco; Sukanta Saha; Uchechukwu Sampson; Lidia Sanchez-Riera; Ella Sanman; David C Schwebel; James Graham Scott; Maria Segui-Gomez; Saeid Shahraz; Donald S Shepard; Hwashin Shin; Rupak Shivakoti; David Singh; Gitanjali M Singh; Jasvinder A Singh; Jessica Singleton; David A Sleet; Karen Sliwa; Emma Smith; Jennifer L Smith; Nicolas J C Stapelberg; Andrew Steer; Timothy Steiner; Wilma A Stolk; Lars Jacob Stovner; Christopher Sudfeld; Sana Syed; Giorgio Tamburlini; Mohammad Tavakkoli; Hugh R Taylor; Jennifer A Taylor; William J Taylor; Bernadette Thomas; W Murray Thomson; George D Thurston; Imad M Tleyjeh; Marcello Tonelli; Jeffrey A Towbin; Thomas Truelsen; Miltiadis K Tsilimbaris; Clotilde Ubeda; Eduardo A Undurraga; Marieke J van der Werf; Jim van Os; Monica S Vavilala; N Venketasubramanian; Mengru Wang; Wenzhi Wang; Kerrianne Watt; David J Weatherall; Martin A Weinstock; Robert Weintraub; Marc G Weisskopf; Myrna M Weissman; Richard A White; Harvey Whiteford; Steven T Wiersma; James D Wilkinson; Hywel C Williams; Sean R M Williams; Emma Witt; Frederick Wolfe; Anthony D Woolf; Sarah Wulf; Pon-Hsiu Yeh; Anita K M Zaidi; Zhi-Jie Zheng; David Zonies; Alan D Lopez; Christopher J L Murray; Mohammad A AlMazroa; Ziad A Memish
Journal:  Lancet       Date:  2012-12-15       Impact factor: 79.321

9.  Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT).

Authors:  Eric D Bateman; Kenneth R Chapman; Dave Singh; Anthony D D'Urzo; Eduard Molins; Anne Leselbaum; Esther Garcia Gil
Journal:  Respir Res       Date:  2015-08-02

Review 10.  Determinants and outcomes of physical activity in patients with COPD: a systematic review.

Authors:  Elena Gimeno-Santos; Anja Frei; Claudia Steurer-Stey; Jordi de Batlle; Roberto A Rabinovich; Yogini Raste; Nicholas S Hopkinson; Michael I Polkey; Hans van Remoortel; Thierry Troosters; Karoly Kulich; Niklas Karlsson; Milo A Puhan; Judith Garcia-Aymerich
Journal:  Thorax       Date:  2014-02-20       Impact factor: 9.139

View more
  5 in total

1.  Accelerometer-Based Physical Activity Patterns and Associations With Outcomes Among Individuals With Osteoarthritis.

Authors:  Tyler Beauchamp; Liubov Arbeeva; Rebecca J Cleveland; Yvonne M Golightly; Derek P Hales; David G Hu; Kelli D Allen
Journal:  J Clin Rheumatol       Date:  2022-03-01       Impact factor: 3.902

2.  Evaluating the impact of morning symptoms in COPD using the Capacity of Daily Living during the Morning (CDLM) questionnaire.

Authors:  Alexa Núñez; Cristina Esquinas; Miriam Barrecheguren; Myriam Calle; Ricard Casamor; Marc Miravitlles
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-11-26

3.  Objectively Monitoring Amyotrophic Lateral Sclerosis Patient Symptoms During Clinical Trials With Sensors: Observational Study.

Authors:  Luis Garcia-Gancedo; Madeline L Kelly; Arseniy Lavrov; Jim Parr; Rob Hart; Rachael Marsden; Martin R Turner; Kevin Talbot; Theresa Chiwera; Christopher E Shaw; Ammar Al-Chalabi
Journal:  JMIR Mhealth Uhealth       Date:  2019-12-20       Impact factor: 4.773

4.  Circadian rhythm of COPD symptoms in clinically based phenotypes. Results from the STORICO Italian observational study.

Authors:  Nicola Scichilone; Raffaele Antonelli Incalzi; Francesco Blasi; Pietro Schino; Giuseppina Cuttitta; Alessandro Zullo; Alessandra Ori; Giorgio Walter Canonica
Journal:  BMC Pulm Med       Date:  2019-09-09       Impact factor: 3.317

5.  The Relationship Between Morning Symptoms and the Risk of Future Exacerbations in COPD.

Authors:  Tian Sun; Xiaoyun Li; Wei Cheng; Yating Peng; Yiyang Zhao; Cong Liu; Yuqin Zeng; Yan Chen; Shan Cai; Ping Chen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-08-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.